MASH

Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH).

Madrigal CEO

Biotech

‘It’s making a difference’: Madrigal CEO talks MASH dealmaking

“We want anything that makes sense mechanistically or has proven already to have an effect on MASH,” CEO Bill Sibold told Fierce in an interview.

Will Maddox Aug 3, 2026 8:00am

liver

D&D sees fibrosis improvements, MASH resolution on GLP-1 drug

May 27, 2026 10:30am

blood test vial

New Hepta blood test could predict GLP-1 response

May 9, 2026 3:08am

Liver

Madrigal boosts MASH pipeline with $1B biobucks Arrowhead deal

May 5, 2026 10:40am

liver

Madrigal pens $4.4B deal for siRNA drugs in fresh Rezdiffra play

Feb 11, 2026 7:40am

target reach ladder climb meet win beat competition

OrsoBio hits target in midstage study for metabolic conditions

Feb 10, 2026 8:00am